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Abstract
Invasive aspergillosis (IA) is a disease that is difficult to manage and is associated 
with a significantly high morbidity and mortality, caused by different species of 
the genus Aspergillus, and closely related to immunocompromised patients; thus, 
it is important to understand the distribution and molecular epidemiology of the 
species causing this disease. Even though Aspergillus fumigatus sensu stricto is the 
most common species that cause IA, in recent years, there has been an increase in 
the number of species in the different sections which makes the diagnosis of this 
invasive fungal disease a great challenge. Conventional tests for the diagnosis of 
IA present limitations in sensitivity and specificity, while molecular tests have the 
potential to improve diagnosis by offering a more sensitive and rapid identification, 
but they are not yet standardized for reliable use in clinic. Nevertheless, there are 
some tests for the presumptive diagnosis of aspergillosis which, although are not 
specific for the identification of species, have been decisive in the case of IA. Among 
these are the Galactomannan test (GM), the Beta-D-glucan assay and volatile 
organic compounds (VOCs) testing. In this chapter, the recent advances and chal-
lenges in the molecular diagnosis of IA are revised.
Keywords: molecular diagnosis, invasive aspergillosis, PCR, epidemiology,  
molecular markers
1. Introduction
Aspergillosis is defined as tissue damage caused by fungi of the genus Aspergillus 
[1], which belongs to the class Ascomycetes. This genus consists of 8000 opportu-
nistic and saprobic fungal species that have been reclassified as 250 species in nine 
primary sections: Flavi, Fumigati, Nigri, Udagawae, Cricumdati, Versicolor, Usti, 
Terrei and Emericella [2, 3]. Members of the genus Aspergillus are filamentous fungi 
that are ubiquitous in the environment [4, 5] and primarily develop close to decom-
posing plants, organic waste and soil, where they produce large numbers of conidia 
that are disseminated through the air [6].
Aspergillus is a cosmopolitan fungus that primarily infects immunocompromised 
hosts and individuals with the underlying lung disease. Some Aspergillus species are 
capable of causing a wide variety of diseases in humans and animals, collectively 
known as aspergillosis, which have increased significantly in recent years [7]. 
Approximately, 45 species have been reported to cause disease in humans [2, 8].
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Aspergillosis can cause several clinical symptoms in humans, especially in immu-
nocompromised individuals [8]. A. fumigatus sensu stricto is the most important oppor-
tunistic human pathogen, producing thousands of airborne conidia, which, due to 
their small size (2.5–3.5 μm in diameter), can be disseminated great distances by atmo-
spheric disturbances such as wind convection currents and can survive under a wide 
range of environmental conditions. These airborne conidia can eventually be inhaled 
into the lungs of humans and animals, where an efficient innate immune response is 
required to prevent infection [8]. The primary diseases associated with this pathogen 
are allergic bronchopulmonary aspergillosis, chronic pulmonary aspergillosis, and 
IA, the latter of which is difficult to manage, leading to a significantly high morbidity 
and mortality. IA is the most serious disease caused by this fungus since it involves the 
invasion of fungal hyphae into tissue, and in some cases, haematogenously spread to 
other organs, particularly the brain [8]. The primary site of IA infection is the lungs. 
Infections of the skin and cornea may also occur, but fungal colonization of these sites 
is much less frequent. IA is rare in healthy individuals and almost exclusively affects 
patients with compromised immune systems [8–13]. The prognosis for these patients is 
often poor due to the scarcity of effective treatments combined with the already com-
promised state of health of these individuals, with mortality rates ranging between 30 
and ≥90% depending on the immune status of the patient [14]. To reduce mortality 
in patients with IA, von Eiff et al. [15] administered empirical antifungal therapies to 
patients with severe neutropaenia (absolute granulocytosis of ≤500/μl) and observed 
a 90–41% reduction in mortality. However, this non-specific strategy has caused an 
increase in resistance to antifungals in patients undergoing long-term treatment [16]. 
In addition, some species belonging to the complex A. fumigatus sensu latu (Fumigati 
section) have been recognized as occasional causes of IA [17–20], and other IA-causing 
species belong to different Aspergillus sections or complexes (Table 1).
Country *Total Rate/100,000 Reference
Algeria 2865 7.1 [21]
Bangladesh 5166 3.2 [22]
Belgium 675 6.08 [23]
Brazil 8664 4.47 [24]
Burkina Faso 54a 0.3 [25]
Cameroon 1175 5.3 [26]
Canada 566 1.59 [27]
Chile 296 1.7 [28]
Colombia 2820 5.7 [29]
Czech Republic 297 2.8 [30]
Ecuador 594 1.3 [31]
Egypt 9001 10.7 [32]
France 1185 1.8 [33]
Greece 1125 10.4 [34]
Guatemala 671 4.4 [35]
Hungary 319b 3.2 [36]
Jordan 84 1.34 [37]
Kazakhstan 511 2.8 [38]
Korea 2150 4.48 [39]
Malaysia 1018 3.3 [40]
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2. Taxonomy of the genus Aspergillus
The genus Aspergillus belongs to the order Eurotiales and includes over 344 spe-
cies, more than 40 of which are aetiological agents of opportunistic human infec-
tions, although some of them do so only occasionally [59].
Aspergillus is traditionally classified based on morphological characteristics, 
such as the size and arrangement of the aspergillary heads, the color of the conidia, 
the growth rate in different media and physiological characteristics. According 
to these morphological characteristics, Raper and Fennell [60] divided the genus 
Aspergillus into 18 groups. However, because this classification did not have any 
status in the nomenclature, Gams et al. [61] introduced the use of Aspergillus 
subgenera and sections. These studies showed that the groups organized by Raper 
and Fennell [60], which were based on phenotypic characteristics, largely coincide 
with the current classifications. However, because morphological variations in 
several sections resulted in controversial taxonomic groups, polyphasic identifica-
tion was used, which involves the morphological, physiological, molecular and 
ecological characterization of a species [3]. Peterson [62] established the acceptance 
of five subgenera (Aspergillus, Circumdati, Fumigati, Nidulantes and Ornati) with 16 
sections from a phylogenetic analysis rDNA region sequences. By contrast, Samson 
Country *Total Rate/100,000 Reference
Mexico 20c 0.017 [41]
4d 0.0036
Nepal 1119 4 [42]
Norway 278 5.3 [43]
Pakistan 10949 5.9 [44]
Peru 1621 5 [45]
Portugal 240 2.3 [46]
Philippines 3085 3 [47]
Qatar 11 0.6 [48]
Romania 1524 7.7 [49]
Russia 3238 2.27 [50]
Spain 4318 9.19 [51]
Thailand 941 1.4 [52]
Tanzania 20 0.05 [53]
Trinidad and Tobago 8 0.6 [54]
Ukraine 1233 2.7 [55]
Uruguay 773 22.4 [56]
United Kingdom 2001-2912e 4.59-4.6 [57]
Vietnam 14523 15.9 [58]
aHaematological malignancies
bChronic obstructive pulmonary disease.
cRenal, heart and liver transplant recipients.
dAllogenic- hematopoietic stem cell transplant.
eAll risk groups except critical care patients.
*Total expected number of cases.
Table 1. 
Estimated burden of invasive aspergillosis.
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and Varga [63], based on phylogenetic analysis using multilocus sequence typing 
(using calmodulin, RNA polymerase 2 and the rRNA gene), subdivided Aspergillus 
into eight subgenres: the subgenus Aspergillus, with the sections Aspergillus and 
Restricti; the subgenus Fumigati, with the sections Fumigati, Clavati and Cervini; 
the subgenus Circumdati, with the sections Circumdati, Nigri, Flavi and Cremei; the 
subgenus Candidi, with the section Candidi; the subgenus Terrei, with the sections 
Terrei and Flavipedes; the subgenus Nidulantes, with the sections Nidulantes, Usti 
and Sparsi; the subgenus Warcupi, with the sections Warcupi and Zonati; and the 
subgenus Ornati, with the section Ornati. Later, Varga et al. [64], based on mul-
tilocus sequence typing (using β-tubulin, calmodulin and the intergenic spacing 
regions [ITS] region), added the subgenus Nidulantes to the Aenei section.
Subsequently, based on different studies [62, 64–66], a new classification was 
proposed for the genus Aspergillus that included four subgenres and 19 sections in 
which the subgenera Ornati and Warcupi were transferred to other genera, since 
they did not belong to the genus Aspergillus. Similarly, the Cremei section, which 
had been classified into the subgenus Aspergillus [62], was reclassified into the 
subgenus Circumdati by Houbraken and Samson [66], resulting in the following 
classification: the subgenus Aspergillus, with the sections Aspergillus (teleomorph 
Eurotium) and Restricti (teleomorph Eurotium); the subgenus Circumdati, with 
the sections Candidi, Circumdati (teleomorph Neopetromyces), Flavi (Petromyces), 
Flavipedes (Fennellia), Nigri and Terrei; the subgenus Fumigati, with the sec-
tions Cervini, Clavati (teleomorph Neocarpenteles, Dichotomomyces) and Fumigati 
(Neosartorya); and the subgenus Nidulantes, with sections Aeni (teleomorph 
Emericella), Bispori, Cremei (teleomorph Chaetosartorya), Nidulantes (teleomorph 
Emericella), Ochraceorosei, Silvati, Sparsi and Usti (teleomorph Emericella). Finally, 
the current classification consists of four subgenera (Aspergillus, Circumdati, 
Fumigati and Nidulantes) and 20 sections [67, 68], with 339 correctly identified spe-
cies [59]. There are currently 45 species of Aspergillus described as human pathogens 
[2], although the number of clinically relevant fungal species has been steadily 
increasing in recent years and is likely to increase further in the future (Table 1).
Colonies of the genus Aspergillus are typically fast growing and can exhibit a 
range of colors, including white, yellow, yellow-brown, brown and black or exhibit 
shades of greenish-gray or blue-green. Aspergillus species are characterized by the 
production of specialized structure, called conidiophores, which in some cases can 
be dramatically different [59]. Although it is a unicellular structure, the conidio-
phore has three distinct parts: the vesicle (swollen apical end), the stipe (cylindri-
cal section located below the vesicle) and the foot cell (final section, sometimes 
separated by a septum that joins the conidiophore with the mycelium). The vesicle 
is partially or entirely covered by an enclosure of phialides (uniseriate). In many 
species, other cells called metulae are located between the vesicle and the phialides 
that support a small number of compact phialides (biseriate). The set forms what 
is called the aspergilar head, which can be strictly uniseriate, biseriate or mixed. 
The conidia are unicellular, round, oval, elliptical, smooth or rough, hyaline or 
pigmented, with thick or thin walls, produced in long chains that can be divergent 
(radiated) or aggregated in compact (columnar) or lax columns (that tend to open). 
Few species produce other types of conidia besides the phialides and metulae on the 
vesicle, and most develop directly on the vegetative hyphae as round or ovoid forms 
called aleuroconidia. Some species can produce Hülle cells, which can be solitary 
or envelop the cleistothecia form of one of the associated teleomorphs. The types 
of known ascomata present great morphological variation, ranging from those 
surrounded by loose hyphae with a smooth pseudoparenchymatous appearance to 
those exhibiting compact sclerotium structures, with variations in size, ornamenta-
tion and type of ascospore surfaces also observed [69].
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The classification of the genus Aspergillus into subgenres and sections is made 
based on four fundamental characteristics: the presence of a teleomorph, the pres-
ence or absence of metulae, the disposition of the metulae or phialides on the vesicle 
and the colouration of the colonies [69].
3. Epidemiology
The number of IA cases has increased in recent years. Recent data provided 
by Bongomin et al. [70] estimate approximately 250,000 cases that occur world-
wide each year, with an associated increase in morbidity and mortality rates. This 
increase is of great importance for health-care systems, since the epidemiological 
surveillance systems in several countries are inefficient. When combined with 
the difficulties in diagnosing IA, the resulting delay in the application of timely 
treatment can lead to the death of patients (Table 2). Given the importance of 
this disease, several research groups have developed ‘The Aspergillus guide’, which 
includes diagnostic and therapeutic guidance, focusing on life-threatening diseases 
caused by Aspergillus spp., primarily in Europe [71].
The major risk factors for developing IA are neutropaenia, allogeneic trans-
plantation of hematopoietic stem cells or solid organ transplantation (particu-
larly lung), haematologic malignancy and chemotherapy with cytotoxic cancer. 
Patients with chronic granulomatous disease and advanced AIDS also have a high 
risk of developing IA, as do patients receiving treatment with chronic steroid 
therapies and tumor necrosis factor as well as those with long-term chronic 
Species Identification method Reference
A. ustus (100) Culture and molecular typing (RAPD) [72]
Emericella quadrilineata (4) Sequence-based analysis
[ITS region, β-tubulin (benA) and calmodulin (caM)]
[73]
A. viridinutans Sequence-based analysis
(β -tubulin and rodlet A gene)
[74]
A. udagawae Sequence-based analysis
[β-tubulin (benA)]
[75]
A. fumigatus (32)
A. lentulus (4)
A. calidoustus (2)
A. tubingensis (1)
A. sydowii (1)
A. flavus (1)
A. terreus (1)
E. rugulosa (1)
Sequence-based analysis
[ITS region, β-tubulin (benA) and calmodulin (caM)]
[76]
Section Usti:
A. calidoustus
Section Fumigati:
A. novofumigatus
A. viridinutans
Sequence-based analysis
[β-tubulin (benA)]
[77]
E. nidulans
var. echinulata
Sequence-based analysis
[ITS region, β-tubulin (benA) and calmodulin (caM)]
[78]
A. lentulus Sequence-based analysis
[ITS region, β-tubulin (benA) and calmodulin (caM)]
[79]
A. lentulus Culture
Thermotolerence
Sequence-based analysis
[ITS region, β-tubulin (benA)
[80]
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diseases and other conditions, such as diabetes mellitus, rheumatological condi-
tions, liver disease and chronic obstructive disease [8–13, 86–88]. It is also impor-
tant to know the distribution and molecular epidemiology of Aspergillus species 
obtained from clinical and environmental sources in different geographical 
regions of the world, since different Aspergillus species can cause IA. In addition, 
although the Fumigati section (complex A. fumigatus) has been reported as the 
most frequent cause of IA, data suggest that IA can be caused by other species in 
immunocompromised hosts (Table 2), especially A. niger, A. terreus and species 
of the complex A. flavus. Therefore, the precise identification of Aspergillus spe-
cies isolated from patients is of great importance for the selection of an effective 
antifungal therapy [84].
Because Aspergillus species are widely distributed fungi in the environment, 
and their conidia are dispersed primarily through air currents, their relation-
ship with hosts in hospital environments is of great relevance. Standards have 
been established for hospital environments for adults and immunosuppressed 
children who require special attention. Ullmann et al. [71] recommend that 
patients should be separated from areas under construction or renovation and 
from potted plants and flowers in patient rooms and living quarters. In addition, 
they recommend placing patients in special rooms with positive air pressure 
and HEPA filters or laminar air flow and rooms with filters for water supplies, 
especially in showers.
Species Identification method Reference
Culture:
A. fumigatus (72.7)
A.flavus (27.3)
Nested PCR:
A. fumigatus (30)
A.flavus (20)
Real-time PCR:
A. fumigatus (6.25)
A. flavus (12.5)
Culture (standard morphological procedures)
Nested PCR
Real-time PCR
[81]
Section Circumdati:
A. pallidofulvus (6.66)
A. ochraceus (2.22)
Section Flavi:
A. tamari (8.88)
Section Terrei:
A. niveus (6.66)
Section Versicolor:
A. sydowii (8.88)
Section Aspergillus:
A. montevidensis (6.66)
Section Nigri:
A. brunneoviolaceus (4.44)
Culture (standard morphological procedures)
Sequence-based analysis
[β-tubulin (benA) and calmodulin (caM)]
MALDI-TOF MS
[82]
A. fumigatus (28.8)
A. flavus (7.2)
Sequence-based analysis:
[ITS region, β-tubulin (benA)]
[83]
A. flavus complex (15)
A. tubingensis (3)
A. fumigatus (2)
Sequence-based analysis:
(region, β-tubulin (benA)
[84]
Section Nidulantes:
A. sublatus (1)
Scanning electron microscopy of ascospores
Sequencing of calmodulin gene
[85]
Table 2. 
Species associated with invasive aspergillosis (IA).
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4. Molecular diagnosis
Accurate and early diagnosis of an active Aspergillus infection is necessary to 
initiate effective antifungal therapy, particularly in critically ill patients [89]. The 
IA diagnosis is made based on the criteria defined for proven, probable or possible 
infection, implemented by the European Organization for Cancer Research and 
Treatment/Study Group on Mycoses (EORTC/MSG). These criteria depend on the 
clinical manifestations, host and fungal factors as well as the results of traditional 
laboratory methods (histopathology and culture) [90, 91]. However, the diagnosis 
of IA continues to be a challenge, since histopathology and cultures have limita-
tions in their sensitivity and specificity as well as in the time required to obtain 
the results, which leads to significant delays in the initiation of treatment [89]. To 
achieve an accurate diagnosis and timely and effective treatment, molecular tests 
have been developed that overcome the limitations of conventional methods and 
can reduce the mortality rate associated with IA [92]. Thus, Samson et al. [59] sug-
gested using a polyphasic approach (morphological characterization, physiological 
tests, ecological data, extrolite analysis and DNA sequencing) as a gold standard 
for the identification of Aspergillus species. However, because these methodologies 
are time and labour intensive, they are not practical in most clinical laboratories. 
Therefore, different PCR modalities have been developed through the use of specific 
molecular markers for the detection of Aspergillus species of medical importance to 
quickly identify the aetiological agent of aspergillosis [93, 94].
Molecular tests for the diagnosis of IA have been developed for both home 
and commercial use to directly detect and identify Aspergillus spp. in different 
clinical specimens, including the following: whole blood, serum, plasma, bron-
choalveolar lavage (BAL), sputum, bronchial aspirate, tissue, pleural effusion and 
cerebrospinal fluid (CSF), allowing for the PCR amplification of fungal DNA via 
nested, multiplex and real-time PCR [89, 93, 95–105] and with minor frequency via 
isothermal amplification (loop-mediated isothermal amplification, LAMP) [106]. 
The efficiency of these tests is variable and depends on many factors, including the 
DNA extraction method, clinical sample type, type of PCR, amplification target 
and detection method. The lack of standardization of these technical problems 
represents the most important barrier for the widespread application of PCR as a 
diagnostic modality for the diagnosis of IA [107].
4.1 DNA extraction methods
The quality and quantity of DNA available for amplification depends on the 
extraction method used. Home, commercial and automated methods for DNA 
extraction are available. In the home, enzymatic, chemical or physical agents are 
used to break the cell wall, while sodium dodecyl sulphate, beta-mercaptoethanol 
and ethylenediaminetetraacetic acid are used to lyse the membrane. The elimination 
of proteins and purification of the DNA is performed by an extraction with phenol-
chloroform, after which the purified DNA is precipitated with alcohol [91]. DNA 
can also be extracted using commercial methods or kits, such as the Qiagen QIAmp 
Tissue Kit (Hilden, Germany), but they are disadvantageous in that the efficiency of 
fungal DNA extraction can vary considerably between different commercial brands. 
Furthermore, for both the home-based and commercial methods, contamination of 
the extraction systems and reagents has been reported, which contributes to varia-
tions in the sensitivity and specificity of the tests. The use of automated methods, 
such as MagNA Pure LC (Roche Diagnostics, Basel, Switzerland), is a viable and 
high-performance option for DNA extraction but may be cost-prohibitive in many 
in-hospital laboratories with limited resources [91, 108].
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4.2 Types of clinical samples
The direct detection of Aspergillus DNA has primarily been performed in whole 
blood, serum, plasma, and BAL, and occasionally in other specimens, such as spu-
tum, bronchial aspirate, tissue, pleural effusion, peritoneal fluid and cerebrospinal 
fluid. It has been observed that the interpretation of results is easier when sterile 
samples are used than when non-sterile samples are used, such as BAL, since the 
ubiquity of the fungus can promote its presence in the upper respiratory tract, mak-
ing colonization, invasion or contamination difficult to determine. To date, the most 
appropriate clinical sample for the diagnosis of IA has not been defined. However, 
the use of total blood and its fractions (serum or plasma) are the most widely used, 
the ease at which both blood can be obtained and the interpretation of results. The 
optimal blood fraction for the detection of Aspergillus DNA is unknown. Studies 
have been conducted to identify the ideal hematological sample to detect Aspergillus 
DNA, taking into account that the processing of whole blood and plasma requires 
the use of an anticoagulant, such as EDTA, which could inhibit PCR. It has been 
observed that the greatest inhibition occurs when using heparin or sodium citrate as 
an anticoagulant [109]. Some authors consider that from a practical point of view, 
serum is the best hematological sample for the detection of Aspergillus DNA, since it 
is easier to process and allows for antigens to be detected at the same time [98]. Other 
authors have shown that the sensitivity of PCR in serum and blood is similar, since 
the levels of circulating A. fumigatus DNA are between 100 fg/ml and 1 ng/ml, both in 
serum and in whole blood. They also report that the sensitivity may increase when a 
combination of serum and blood is used, which can perhaps be explained by the fact 
that the performance of DNA detection improves when large volumes of samples are 
used, rather than by the combination of the two per se [95, 98, 109, 110]. Meanwhile, 
Springer et al. [111] reported that PCR performed using plasma showed a higher 
sensitivity (91%) than for serum (80%) and whole blood (55%). These observations 
contrast with previous reports, possibly due to differences in sample processing [107].
BAL has also been used to detect Aspergillus by PCR, showing promising and 
contradictory results. In clinical studies, the general ranges of sensitivity and 
specificity varied widely, from 73 to 100% and 80 to 100%, respectively, depending 
on the characteristics of the trial and the type of patients evaluated. The majority of 
PCR studies using BAL have been performed using patients with haemato-oncologi-
cal disorders. While some studies demonstrated a high specificity [100], others have 
shown greater sensitivity [112] or high sensitivity and specificity [99].
Other types of samples that have been used are lung or other deep-tissue biop-
sies, CSF and pleural effusion, which provided acceptable values of sensitivity and 
specificity [102, 103, 113]. However, its applicability in routine laboratory diagnos-
tics is limited by the difficulty in obtaining this type of specimen.
4.3 Types of PCR
Nested PCR has been successfully used to detect Aspergillus spp. [102]. However, 
this technique is not the most suitable format, since although the process allows for 
great sensitivity, there is also the possibility of contamination and the generation of 
false-positive results. Multiplex PCR has also been used to detect Aspergillus spp., 
particularly in BAL samples. However, despite its adequate specificity and sensitivity 
(0.01 ng of DNA) [93], the detection method required (electrophoresis in an agarose 
gel) limits its application as a diagnostic tool, since results in this setting are expected 
to be obtained as quickly as possible. The primary limitation of these end-point 
PCR formats is the inability to differentiate between colonization or active infec-
tion. In 2006, the European Aspergillus PCR Initiative (EAPCRI) sought proposals 
for a technical consensus. This consensus was possible thanks to the generalization 
9Molecular Diagnosis of Invasive Aspergillosis
DOI: http://dx.doi.org/10.5772/intechopen.78694
of real-time quantitative PCR (qPCR). This technique drastically reduces the risk 
of contamination, allows quantitative management of the amplification reaction 
(quantification of the fungal load), differentiates between several pathogenic species 
when multiple probes are used in a single assay and allows for the result to be known; 
at the same time, the amplification is carried out, which helps establish an effective 
treatment in a timely manner [114]. Therefore, most of the PCR assays that have 
been developed for the diagnosis of IA are in a real-time format, primarily using 
hydrolysis probes (TaqMan) directed at the 18S, 28S and ITS regions [91].
Another alternative to detect Aspergillus is LAMP. This technique offers several 
potential advantages over PCR, among which is a more efficient amplification, 
the possibility of evaluating cell viability, a reduction in the contamination of the 
genetic material to be amplified and the possibility of using RNA as a target instead 
of DNA. The latter advantage allows for a greater sensitivity since highly expressed 
genes produce thousands of transcripts within a cell [106, 107].
4.4 Molecular marker or amplification targets
The selection of a molecular marker or a target region for PCR amplification to 
diagnose IA is of great importance, since it must favor a sensitive and specific ampli-
fication. The most commonly used markers to achieve high sensitivity in detecting 
Aspergillus spp., both in home and in commercial PCR assays, are multicopy genes, 
such as the ribosomal 18S and 28S genes, for which hundreds of copies are present in 
the genomes of Aspergillus spp. [89, 95, 97, 99, 102–105]. The disadvantage of using 
multicopy genes is that they involve highly conserved sequences in fungi, leading to a 
limited specificity (panfungal PCR). This type of amplification target does not always 
allow the differentiation of phylogenetically related species, such as species that are 
within the same section, which can often be important. For example, in the Fumigati 
section, although A. fumigatus, A. lentulus and N. udagawe are closely related, the latter 
two species are more resistant to antifungals than A. fumigatus. This PCR method may 
not even be able to distinguish between phylogenetically related genera (Aspergillus, 
Penicillium and Paecilomyces spp.), representing a problem in the selection of antifungal 
treatments [99]. Strategies have been designed to overcome the lack of specificity of 
multicopy genes, such as hybridization with species-specific probes [112]. Similarly, the 
variable regions of the rRNA gene, the ITS regions and D1/D2 are used [98, 100, 115]. 
ITS sequences may lack sufficient variation for the resolution of some Aspergillus spe-
cies, and a bar code or a secondary identification marker is typically needed to identify 
an isolate at the species level. Based on these observations, the use of sequencing gene 
fragments, such as α-tubulin (benA) or calmodulin (caM), has been recommended for 
the identification of individual species within sections [107]. Single-copy genes have 
also been used as molecular markers in the diagnosis of IA, which provide a greater 
specificity to the assay but a lower sensitivity. The single-copy genes that have been used 
include aspHS, SCW4 and anxC4, which have shown promising results for detecting  
A. fumigatus, A. flavus, A. niger, A. nidulans, A. terreus and A. versicolour in BAL samples 
[93, 101, 106]. Because the aspHS gene encodes a haemolysin that is overexpressed in 
vivo during infection, its detection provides specificity to differentiate an active infec-
tion (germinated conidia) from a non-active one (non-germinated conidia) [101].
4.5 Resistance markers
PCR has also been used to detect resistance to antifungals, since an increasing 
number of environmental and clinical A. fumigatus isolates with a lower suscep-
tibility to azoles have been observed. Infections caused by azole-resistant fungi 
are associated with a very high mortality rate. The available evidence suggests that 
resistance may be emerging as a result of the widespread use of these compounds in 
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agricultural and clinical settings. The predominant resistance mechanism involves 
mutations in the cyp51A gene (L98H, Y121F, T289A and TR34), which encodes sterol 
demethylase, the target of azoles, and it has been shown that a variety of these 
mutations confer resistance to azoles. Molecular resistance tests have been used to 
assess fungal isolates as part of epidemiological surveillance studies of drug resis-
tance and have been used to assess clinical isolates as a complement to phenotypic 
susceptibility testing. Real-time multiplex PCR has also been used to directly detect 
azole-resistant Aspergillus in BAL samples from patients at IA risk. However, more 
studies are needed to determine its potential utility in clinical care [107, 112].
5. Other diagnostic methods
Nowadays, there are some tests for the presumptive diagnosis of aspergillosis 
which, although are not specific for the identification of species, have been decisive 
in the case of IA. Among these are the Galactomannan test (GM), the Beta-D-glucan 
(BDG) assay and volatile organic compounds (VOCs) testing.
5.1 Galactomannans
The GM is a polysaccharide, the main component of the Aspergillus cell wall, 
which binds to and is released from the hyphae during growth [116, 117]. The 
galactomannan is not only found in the walls of Aspergillus but also in the cell walls 
of other fungi such as Fusarium spp., Histoplasma capsulatum, Penicillium spp., 
Paecilomyces spp. and to a lesser extent in other fungi [109, 118–121].
One of the most widely used tests for its determination is Platelia™ 
Aspergillus EIA (immunoenzymatic sandwich microplate assay), which uses 
monoclonal antibodies that are directed against the GM of Aspergillus  
[117, 122–124]. The real interest of this test in the diagnosis of aspergillosis lies 
in the fact that the galactomannan represents a good indirect indicator of the 
fungus [119] once it is released into the bloodstream; furthermore, it can be 
detected in body fluids such as serum, bronchoalveolar lavage (BAL), cerebro-
spinal fluid or pleural fluid [118].
Currently, it is considered as a serological method that facilitates the diagnosis 
of IA [125], even though it presents a highly variable sensitivity which ranges from 
40 to 100% and depends on the population to be evaluated. Hachem et al. [118] 
showed in a study with patients suffering from haematologic malignancies associ-
ated to IA produced by Aspergillus non-fumigatus a sensitivity of 49%, whereas 
patients that presented IA by A. fumigatus sensu stricto showed a sensitivity of 
13%, and the specificity was of 99% in both groups. Another study conducted by 
Maschmeyer et al. [126] reported that in patients undergoing chemotherapy for 
cancer or patients with hematopoietic stem cell transplantation, the sensitivity of 
the GM was of 67–100% and the specificity was of 86–99%. The meta-analysis con-
ducted by Leeflang et al. [117] in patients with neutropaenia showed a sensitivity 
and a specificity of 78 and 81%, respectively. Pfeiffer et al. [116] found a sensitivity 
and a specificity of 95% in patients with hematopoietic stem cell transplant and 
solid organ transplants, respectively. It is important to highlight that the detection 
of GM in patients on antibacterial treatment results in the reduction of the test’s 
specificity, while in patients on antifungal treatment, the sensitivity decreases in 
most cases. However, this does not occur when using caspofungin which increases 
the sensitivity [109, 127]. It is necessary to consider that when using bronchoalveo-
lar lavage (BAL) to determine galactomannans, the test increases its sensitivity and 
turns out to be a more useful mortality prediction test [128].
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5.2 ΒDG
The ß-glucans are glucose polymers (polysaccharides) of high-molecular weight 
that are found naturally in the cell wall of various organisms, such as bacteria, yeasts, 
fungi and plants. The BDG is produced by most fungi of medical importance such 
as Candida spp., Aspergillus spp. and Pneumocystis jirovecii. Among the fungi that 
release little BDG in serum, there can be found Mucorales fungi and Cryptococcus 
[129]. This antigen is important in fungal infections as it is released during the infec-
tion and has a higher sensitivity for the diagnosis of IA compared to GM and can be 
detected in the plasma of patients with mycosis. Therefore, this antigen can be used 
as a marker of fungal infection although it does not allow the identification of species 
[130] and is included as a diagnostic criterion in the European Organization for 
Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) [90, 131].
For the detection of BDG, the Fungitell assay (Cape Cod Associates, Inc.) is 
used, which was approved by the Food and Drug Administration in 2003 for the 
presumptive diagnosis of IFI [132]. For this test, the results are variable in differ-
ent studies, with sensitivity values ranging from 80 to 90% and specificity values 
from 36 to 92%, according to the cut-off value used [133, 134]. In studies with 
patients suffering from haematologic malignancies who develop IA, the sensibility 
of the test varies from 55 to 95%, and the specificity from 77 to 96% [133, 135]. It 
is important to mention that data from existing clinical studies for the Fungitell 
assay, which is the most widely used test today, suggest that the use of a detection 
limit of 80 pg/ml is associated with a greater precision than those with a result of 
60–80 pg/ml, which are considered as indefinite. The above indicates that higher 
cut-off values dramatically decrease the sensitivity of the test, whilst increasing its 
specificity [135, 136].
The β-D-glucan assay is often useful in combination with culture, as it improves 
conditions for success [135]. Several factors that may increase the levels of BDG 
on IFI have been identified, such as thrombocyte infusions with leukocyte deple-
tion filters, hemodialysis with cellulose membranes [137], the use of antibiotics 
such as amoxicillin-clavulanic acid or piperacillin-tazobactam [138], the use of 
surgical gauzes containing glucan, the administration of human blood products 
(immunoglobulins or albumin), severe mucositis and the presence of serious bacte-
rial infections [129]. On the other hand, Pickering et al. [139] reported that high 
concentrations of bilirubin and triglycerides inhibit the levels of BDG and cause 
false-negative results, while hemolysis causes false-positive results.
5.3 Volatile organic compounds (VOCs)
The air exhaled by patients with invasive diseases contains a large number of 
VOCs, produced by different metabolic pathways, which can be used as biomarkers 
of pulmonary disease [109, 140]. Several techniques have been used to determine 
VOCs, like the gas chromatography and mass spectrometry which is impractical for 
use in the clinic [141–143]. One alternative seems to be the use of electronic noses 
and artificial olfactory systems that use a series of sensors that help discriminate 
each smell that represents a unique blend of VOCs, which function through pattern 
recognition algorithms called ‘breathprints’ [144, 145]. Several volatile organic com-
pounds characteristic of Aspergillus spp. have been identified such as 3-octanone, 
isoamyl alcohol, ethanol, cyclohexanone, 2-methyl-2-propanol, 2-methylfuran, 
2-ethyl-1-hexanol and 2-pentylfuran, among others [141–143, 146].
Among the advantages of these devices are their low cost, most of them are 
manual, easy to operate and provide results in few minutes. With regard to the 
benefits for the patient, they are non-invasive tests, safe, fast and easy to perform. 
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The sensitivity and specificity of this test is of 100 and 83.3%, respectively, which 
makes it one of the best options for the diagnosis of IA [140].
It is necessary to consider that in order to validate all these tests, more studies 
that provide additional advantages for their use must be conducted.
6. Discussion and conclusions
Currently, IA has become very important among fungal infections around the world 
since the number of cases has increased coupled with a high rate of morbidity and mor-
tality, detected mainly in immunocompromised patients. The A. fumigatus complex has 
been reported as the most frequent cause of IA in immunocompromised hosts. During 
the last few years, new species have been described that belong to other complexes that 
also cause this disease, which represents a challenge to understand the epidemiology 
of this nosological entity. On the other hand, the appearance of new species causing 
IA generates problems to establish its diagnosis since conventional methods continue 
to be used, which fail to discriminate between closely related species, such as imaging, 
histopathology, microscopy and culture procedures. These last ones are still considered 
the gold standards even though they have a low sensitivity and are time-consuming 
[109]. Other methods that have been considered important are immunological methods 
to detect GM and BDG antigens in serum and other biological fluids. They also have 
limitations, such as cross reactions with other fungal species and interference with 
antibiotics such as b-lactams or with plasma infusion solutions [147]. In addition, these 
methods only identify the fungus at the complex level. It is important to identify the 
species, since recently, the presence of ‘cryptic’ Aspergillus species has been revealed in 
clinical samples of IA, which present differences in the susceptibility to antifungals, as 
is the case of voriconazole considered as the therapy of choice for invasive aspergillosis. 
The effectiveness of this drug is uncertain in the cryptic Aspergillus species, since it has 
been shown that resistance to multiple antifungal drugs is frequent, particularly in  
A. lentulus, A. alliaceus, A. sydowii, A. calidoustus, A. keveii, A. insuetus and A. fumiga-
tiaffinis [19]. Currently, there is more awareness of the need to identify Aspergillus at the 
species level. This can be achieved through a polyphasic strategy [3]. In addition to the 
phenotypic characteristics, it includes the analysis of multilocus sequences, as well as 
PCR with specific probes for each species, such as multiplex qPCR, to identify clinically 
relevant Aspergillus species from the complex A. fumigatus, A. terreus, A. flavus, A. niger 
and A. nidulans [112]. However, molecular methods have not yet been recognized as 
diagnostic criteria for the identification of invasive fungal infection (IFI) by EORTC/
MSG, due to the lack of standardization protocols, and the significant rates of false 
positives and false negatives. In addition, it should be considered that before its imple-
mentation in routine clinical practice, each diagnostic test must follow a long validation 
process, which involves various aspects such as limit of sensitivity, reproducibility and 
precision, so that the task is nothing simple; however, its use is paramount, so several 
recent studies have evaluated its application [108, 109, 148].
Therefore, it is clear that despite the efforts made so far to implement effective 
diagnostic methods, there is still no consensus about which is the ideal method. 
Therefore, as long as these methods are not standardized and their reliability is not 
guaranteed to improve the detection of Aspergillus spp. in an effective and timely 
manner, the diagnosis of IA will continue to represent a challenge.
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